What Will Take For AYTU To Reach $20 A Share - CWEB.com

What Will Take For AYTU To Reach $20 A Share - CWEB.com

For men suffering with low testosterone Aytu Bioscience's  (OTCQX:AYTU)FDA-approved, Natesto, a nasally administered TRT is a more effective and safer treatment than TLANDO.

Natesto has the added advantage of not affecting LH and FSH hormone levels.

Aytu Bioscience (OTCQX:AYTU) competitors  Lipocine's (LPCN) TLANDO medication for men with low testosterone was turned down on 1/10/2018, by the FDA's Bone, Reproductive and Urologic Drugs Advisory Committee. 

The FDA voted 13-6 against Lipocine's (LPCN) TLANDO with concerns raised about risks to patients.

Currently  Lipocine's (LPCN) is trading around $1.63

So  Aytu Bioscience (OTCQX:AYTU) is a lot cheaper with a higher potential and trading around 0.63 cents.

On January 10, 2018, both Clarus (OTC:CLAR) Therapeutics which trades around $6.70 and Lipocine's (LPCN) got a thumbs down from the FDA.

So the bottom line is that  Aytu Bioscience (OTCQX:AYTU) is trading at it lowest levels with already approved medicine by the FDA versus it's competitors that got rejected by the FDA recently.

Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.

Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress.

MiOXSYS® is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Regulatory licenses and registrations are critical to our efforts of effectively penetrating these new markets. MiOXSYS continues to gain traction with its international commercial expansion as regulatory bodies, like Mexico'sCOFEPRIS, approve the product for clinical use in the assessment of male infertility."

Mexico is one of the top ten largest countries in the world, with a population of over 127 million. Approximately one in six couples suffer from infertility, and almost half of these cases can be attributed to male factor infertility. Male infertility assessment remains a significant area of clinical need around the world.

Mr. Disbrow added, "We recently appointed IMP Medica, headquartered in Mexico City, Mexico, as exclusive distributor of the MiOXSYS System in Mexico. We are pleased to now be able to offer MiOXSYS to clinicians and laboratories throughout Mexico who seek to better identify and treat men with suspected infertility and for which oxidative stress may be implicated."

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Aytu BioScience, Inc. (OTCQX:AYTU), is undervalued. 52 Week High traded around $16 before a split.

CWEB Analyst's have initiated a Buy Rating for Aytu BioScience, Inc. (OTCQX:AYTU), and a Price Target of $10 - $20 within 12 months.

Read Full Article and Videos CWEB.com - Trending News, Blog, Shopping

AYTU data by YCharts

[object HTMLElement]

I'm long AYTU